Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
27 10 2022
Historique:
accepted: 30 06 2022
received: 03 12 2021
pubmed: 16 7 2022
medline: 1 11 2022
entrez: 15 7 2022
Statut: ppublish

Résumé

The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with a lineage switch from acute lymphoblastic to acute myeloid leukemia, resulting in poor clinical outcomes caused by resistance to chemotherapies and immunotherapies. In this study, the myeloid relapses shared oncogene fusion breakpoints with their matched lymphoid presentations and originated from various differentiation stages from immature progenitors through to committed B-cell precursors. Lineage switching is linked to substantial changes in chromatin accessibility and rewiring of transcriptional programs, including alternative splicing. These findings indicate that the execution and maintenance of lymphoid lineage differentiation is impaired. The relapsed myeloid phenotype is recurrently associated with the altered expression, splicing, or mutation of chromatin modifiers, including CHD4 coding for the ATPase/helicase of the nucleosome remodelling and deacetylation complex. Perturbation of CHD4 alone or in combination with other mutated epigenetic modifiers induces myeloid gene expression in MLL/AF4+ cell models, indicating that lineage switching in MLL/AF4 leukemia is driven and maintained by disrupted epigenetic regulation.

Identifiants

pubmed: 35839448
pii: S0006-4971(22)00914-4
doi: 10.1182/blood.2021015036
pmc: PMC10488321
doi:

Substances chimiques

Myeloid-Lymphoid Leukemia Protein 149025-06-9
Oncogene Proteins, Fusion 0
Chromatin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1875-1890

Subventions

Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/V001639/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W01677X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S021590/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA215504
Pays : United States
Organisme : Cancer Research UK
ID : 12788
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0802259
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S021469/1
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/P002412/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Haematologica. 2018 Jul;103(7):1169-1181
pubmed: 29599201
Cell Stem Cell. 2018 Sep 6;23(3):412-425.e10
pubmed: 30122475
Nature. 1999 Oct 7;401(6753):556-62
pubmed: 10524622
Cell Stem Cell. 2009 Feb 6;4(2):129-40
pubmed: 19200802
Front Oncol. 2021 Apr 26;11:633233
pubmed: 33981601
Haematologica. 2006 May;91(5 Suppl):ECR09
pubmed: 16709517
Leuk Lymphoma. 2005 Aug;46(8):1223-7
pubmed: 16085566
Cell Rep. 2019 Jul 9;28(2):472-485.e5
pubmed: 31291582
Genes Dev. 2021 Nov 1;35(21-22):1475-1489
pubmed: 34675061
Genes Chromosomes Cancer. 2013 Oct;52(10):954-60
pubmed: 23893660
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
Haematologica. 2019 Jun;104(6):1176-1188
pubmed: 30679323
Leukemia. 2016 Jan;30(1):32-8
pubmed: 26202931
Lancet Oncol. 2010 May;11(5):429-38
pubmed: 20409752
JAMA. 2010 Dec 22;304(24):2706-15
pubmed: 21177505
Leukemia. 2007 Sep;21(9):2000-9
pubmed: 17597811
Nat Commun. 2021 Oct 19;12(1):6078
pubmed: 34667177
Nat Commun. 2021 Feb 8;12(1):865
pubmed: 33558546
Genome Res. 2021 Jun 4;:
pubmed: 34088716
Leukemia. 2010 Oct;24(10):1751-9
pubmed: 20686504
Nat Biotechnol. 2017 Oct 11;35(10):908-911
pubmed: 29020005
Cancer Cell. 2008 Jul 8;14(1):47-58
pubmed: 18598943
Haematologica. 2008 May;93(5):670-9
pubmed: 18367492
Annu Rev Cancer Biol. 2018 Mar;2:271-289
pubmed: 29756093
Blood. 2010 Feb 18;115(7):1394-405
pubmed: 19880498
Nat Med. 2022 Apr;28(4):743-751
pubmed: 35288693
Am J Hematol. 2012 Sep;87(9):890-7
pubmed: 22685031
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4513-22
pubmed: 25288773
Mol Cell. 2002 Nov;10(5):1119-28
pubmed: 12453419
Nat Commun. 2016 Jul 27;7:12320
pubmed: 27460500
Cell Rep. 2017 Jan 10;18(2):482-495
pubmed: 28076791
Nat Genet. 2016 Sep;48(9):1060-5
pubmed: 27479907
Cancer Cell. 2016 Nov 14;30(5):737-749
pubmed: 27846391
Am J Hum Genet. 2011 Apr 8;88(4):440-9
pubmed: 21457909
Exp Hematol. 2021 Aug;100:1-11
pubmed: 34298117
Nature. 2018 Oct;562(7727):373-379
pubmed: 30209392
Cell Rep. 2013 Jan 31;3(1):116-27
pubmed: 23352661
Haematologica. 2018 Dec;103(12):e571-e574
pubmed: 29903765
Nat Genet. 2015 Apr;47(4):330-7
pubmed: 25730765
Cell. 2011 Jan 21;144(2):296-309
pubmed: 21241896
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
Blood. 2011 Mar 10;117(10):2827-38
pubmed: 21239694
J Exp Med. 2017 Mar 6;214(3):773-791
pubmed: 28190000
Stem Cell Reports. 2015 Aug 11;5(2):232-47
pubmed: 26235892
Nat Rev Clin Oncol. 2020 Jun;17(6):360-371
pubmed: 32152485
Immunity. 2009 Apr 17;30(4):493-507
pubmed: 19345118
Mol Cell Biol. 1995 Oct;15(10):5830-45
pubmed: 7565736
Leukemia. 2018 Feb;32(2):273-284
pubmed: 28701730
Proc Natl Acad Sci U S A. 2019 May 28;116(22):10927-10936
pubmed: 31085655
Trends Cancer. 2015 Nov;1(3):157-160
pubmed: 28741472
BMC Med Genomics. 2009 Jun 23;2:36
pubmed: 19549311
Pediatr Blood Cancer. 2016 Jun;63(6):1113-5
pubmed: 26914337
Nat Immunol. 2011 Nov 13;13(1):86-94
pubmed: 22080921
Nucleic Acids Res. 2013 Nov;41(21):e201
pubmed: 24071585
Science. 2014 Sep 26;345(6204):1251033
pubmed: 25258084
Nat Immunol. 2008 Feb;9(2):203-15
pubmed: 18176567
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Blood. 2022 Apr 7;139(14):2173-2185
pubmed: 34871373
Blood. 2015 Sep 17;126(12):1462-72
pubmed: 26265695
Genes Dev. 2008 May 1;22(9):1174-89
pubmed: 18451107

Auteurs

Ricky Tirtakusuma (R)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Katarzyna Szoltysek (K)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.

Paul Milne (P)

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Vasily V Grinev (VV)

Department of Genetics, the Faculty of Biology, Belarusian State University, Minsk, Republic of Belarus.

Anetta Ptasinska (A)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Paulynn S Chin (PS)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Claus Meyer (C)

Institute of Pharmaceutical Biology/DCAL, Goethe-University, Frankfurt/Main, Germany.

Sirintra Nakjang (S)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Jayne Y Hehir-Kwa (JY)

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Daniel Williamson (D)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Pierre Cauchy (P)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Peter Keane (P)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Salam A Assi (SA)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Minoo Ashtiani (M)

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Sophie G Kellaway (SG)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Maria R Imperato (MR)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Fotini Vogiatzi (F)

ALL-BFM Study Group, Pediatric Hematology/Oncology, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Germany.

Elizabeth K Schweighart (EK)

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Shan Lin (S)

Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Mark Wunderlich (M)

Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Janine Stutterheim (J)

Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Alexander Komkov (A)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Elena Zerkalenkova (E)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Paul Evans (P)

Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.

Hesta McNeill (H)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Alex Elder (A)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Natalia Martinez-Soria (N)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Sarah E Fordham (SE)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Yuzhe Shi (Y)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Lisa J Russell (LJ)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Deepali Pal (D)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Alex Smith (A)

Epidemiology and Cancer Statistics Group, University of York, York, United Kingdom.

Zoya Kingsbury (Z)

Illumina Cambridge Ltd., Great Abington, United Kingdom.

Jennifer Becq (J)

Illumina Cambridge Ltd., Great Abington, United Kingdom.

Cornelia Eckert (C)

Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.

Oskar A Haas (OA)

St Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.

Peter Carey (P)

Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.

Simon Bailey (S)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.

Roderick Skinner (R)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.

Natalia Miakova (N)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Matthew Collin (M)

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Venetia Bigley (V)

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Muzlifah Haniffa (M)

Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Department of Dermatology and Newcastle National Institute of Health Research (NIHR), Newcastle Biomedical Research Centre, Newcastle Hospitals National Health Service (NHS) Foundation Trust, Newcastle upon Tyne, United Kingdom.

Rolf Marschalek (R)

Institute of Pharmaceutical Biology/DCAL, Goethe-University, Frankfurt/Main, Germany.

Christine J Harrison (CJ)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Catherine A Cargo (CA)

Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, United Kingdom.

Denis Schewe (D)

Department of Pediatrics, Otto von Guericke University Magdeburg, Magdeburg, Germany.

Yulia Olshanskaya (Y)

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia.

Michael J Thirman (MJ)

Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL.

Peter N Cockerill (PN)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

James C Mulloy (JC)

Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Helen J Blair (HJ)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Josef Vormoor (J)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

James M Allan (JM)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.

Constanze Bonifer (C)

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.

Olaf Heidenreich (O)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.

Simon Bomken (S)

Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Paediatric Haematology and Oncology, The Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH